- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07650292
Wearable-Assisted Walking for Cognitive Function and Loneliness in Older Adults (WAW-CogLon)
Effects of a Wearable-Assisted Walking Program on Longitudinal Trajectories of Cognitive Function and Loneliness in Older Adults: A Randomized Controlled Trial
Participants in the wearable-assisted walking group were asked to walk five days per week for approximately 30 minutes per session at moderate intensity. An Apple Watch was used to monitor daily steps, walking duration, and estimated energy expenditure. Participants also received weekly feedback to support adherence to the walking program. Participants in the usual-care control group were asked to maintain their usual daily activities and not begin any new structured exercise program during the study period.
Cognitive function was measured using the Montreal Cognitive Assessment, and loneliness was measured using the 8-item UCLA Loneliness Scale. Assessments were conducted at baseline and at weeks 4, 8, and 12. The study also explored whether baseline muscle mass and functional mobility were associated with changes in cognitive function and loneliness over time.
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
This randomized controlled trial examined longitudinal changes in cognitive function and loneliness during a 12-week wearable-assisted walking intervention. The intervention combined regular moderate-intensity walking with wearable-device monitoring and weekly feedback. The control group received usual care and maintained their normal daily activities.
The primary outcome was cognitive function, measured using the Montreal Cognitive Assessment. The secondary psychosocial outcome was loneliness, measured using the 8-item UCLA Loneliness Scale. Outcomes were assessed at four time points: baseline, week 4, week 8, and week 12. Baseline appendicular skeletal muscle mass index and timed up-and-go performance were also assessed to examine whether muscle health and functional mobility were associated with individual differences in outcome trajectories.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
New Taipei City, Taïwan, 251301
- National Taiwan College of Performing Arts
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
Age 65 years or older. Community-dwelling older adults recruited from community-based older adult programs in Taiwan.
Ability to walk independently or with minimal assistance. Willingness to be randomized to either the wearable-assisted walking group or the usual-care control group.
Willingness to wear a wearable device if assigned to the intervention group. Ability to understand the study procedures and complete the cognitive, psychological, and physical assessments.
Provision of written informed consent before enrollment and baseline assessment.
Exclusion Criteria:
Severe cardiovascular disease. Recent fracture or surgery. Severe neurological disorders. Severe cognitive impairment that precluded completion of study assessments. Medical contraindications to moderate-intensity walking. Current enrollment in other structured exercise or rehabilitation programs during the study period.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Wearable-Assisted Walking Group
Participants assigned to this group received a 12-week wearable-assisted walking intervention.
They were instructed to walk five days per week, with each session lasting approximately 30 minutes at moderate intensity.
A commercially available Apple Watch was used to monitor daily step counts, walking duration, and estimated caloric expenditure.
Weekly feedback was provided through the LINE messaging application and face-to-face check-ins to support self-monitoring, reinforce walking goals, and monitor adherence.
|
The intervention consisted of a 12-week moderate-intensity walking program supported by a commercially available wearable device.
Participants were instructed to walk five days per week for approximately 30 minutes per session.
Walking intensity was guided by a rating of perceived exertion of 11-13.
An Apple Watch was used to record daily step counts, walking duration, and estimated caloric expenditure.
Weekly feedback was provided through the LINE messaging application and face-to-face check-ins to support self-monitoring, reinforce walking goals, and monitor adherence.
|
|
Aucune intervention: Usual-Care Control Group
Participants assigned to this group were instructed to maintain their routine daily activities and typical lifestyle throughout the 12-week study period.
They were asked not to initiate any new structured exercise or rehabilitation program during the study period.
They did not receive wearable devices, structured walking prescriptions, or weekly activity feedback.
|
|
|
Expérimental: Behavioral
The intervention consisted of a 12-week moderate-intensity walking program supported by a commercially available wearable device.
Participants were instructed to walk five days per week for approximately 30 minutes per session.
Walking intensity was guided by a rating of perceived exertion of 11-13.
An Apple Watch was used to record daily step counts, walking duration, and estimated caloric expenditure.
Weekly feedback was provided through the LINE messaging application and face-to-face check-ins to support self-monitoring, reinforce walking goals, and monitor adherence.
|
The intervention consisted of a 12-week moderate-intensity walking program supported by a commercially available wearable device.
Participants were instructed to walk five days per week for approximately 30 minutes per session.
Walking intensity was guided by a rating of perceived exertion of 11-13.
An Apple Watch was used to record daily step counts, walking duration, and estimated caloric expenditure.
Weekly feedback was provided through the LINE messaging application and face-to-face check-ins to support self-monitoring, reinforce walking goals, and monitor adherence.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Cognitive Function Assessed by the Montreal Cognitive Assessment
Délai: Baseline, week 4, week 8, and week 12
|
Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA), a brief screening tool that evaluates multiple cognitive domains, including visuospatial ability, executive function, attention, memory, language, abstraction, and orientation.
Total scores range from 0 to 30, with higher scores indicating better cognitive performance.
|
Baseline, week 4, week 8, and week 12
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Loneliness Assessed by the 8-item UCLA Loneliness Scale
Délai: Baseline, week 4, week 8, and week 12
|
Loneliness was assessed using the 8-item UCLA Loneliness Scale (UCLA-8), which measures subjective feelings of loneliness and perceived social disconnection.
Items are rated on a 4-point Likert-type scale, with higher total scores indicating greater loneliness.
|
Baseline, week 4, week 8, and week 12
|
|
Secondary Outcome Measure
Délai: Baseline, week 4, week 8, and week 12
|
Loneliness was assessed using the 8-item UCLA Loneliness Scale (UCLA-8), which measures subjective feelings of loneliness and perceived social disconnection.
Items are rated on a 4-point Likert-type scale, with higher total scores indicating greater loneliness.
|
Baseline, week 4, week 8, and week 12
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- IRB115-029-B (Autre identifiant: Research Ethics Committee Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Plan to Share IPD:
Yes
IPD Sharing Plan Description:
Deidentified individual participant data that underlie the results reported in this study may be made available from the corresponding investigator upon reasonable request. Data sharing will be considered after review of the scientific purpose of the request and approval by the investigator, subject to applicable ethical and privacy regulations.
IPD Sharing Supporting Information Type:
Study Protocol Statistical Analysis Plan
Time Frame:
Data may be available beginning 6 months after publication of the main study results and for 3 years thereafter.
Access Criteria:
Researchers who provide a methodologically sound proposal may request access to deidentified data for academic and non-commercial research purposes. Requests should be directed to the corresponding investigator. Data will be shared only after approval of the request and, where applicable, completion of a data use agreement.
URL:
Leave blank
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .